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Interferon a (IFNa) is used to treat patients with advanced renal cell carcinoma (RCC) despite limited clinical benefit. IFNa can induce
Fas receptor-mediated apoptosis by direct activation of pro-caspase-8 followed by activation of caspase-3. Alternative, indirect
activation of caspase-3 via mitochondrial release of cytochrome c can occur and may explain the rescue from Fas-activated cell death
by the antiapoptotic members of the Bcl-2 family. In this study, we examined G3139, a novel antisense compound targeting Bcl-2, in
combination with IFNa. Human RCC lines (SK-RC-44 and SK-RC-07) were treated with IFNa, G3139 or a combination of the two.
Fas-mediated cytotoxicity was induced by anti-Fas mAb, CH11. An analysis of Bcl-2, Fas and the cleavage of PARP was performed.
IFNa induced Fas and Bcl-2 in SK-RC-44 and SK-RC-07. IFNa sensitised SK-RC-44 to anti-Fas and induced PARP cleavage confirming
that IFNa has a cytotoxic effect on RCC lines by induction of the Fas antigen. Cytotoxicity was not evident in SK-RC-07 cells treated
with IFNa. G3139 induced a specific downregulation of Bcl-2 in SK-RC-07 cells, which were then sensitised to anti-Fas after treatment
with IFNa. Taken together, these results suggest that Fas-dependent pathways as well as alternative pathways, which can be inhibited
by Bcl-2, exist in renal cell carcinoma. G3139 in combination with IFNa is a potential therapy in patients with metastatic renal cell
carcinoma.
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Renal cell carcinoma (RCC) is the seventh leading cause of cancer
accounting for 3% of all malignancies. Approximately one-third of
patients with RCC have metastatic disease at presentation, and up
to 50% relapse following nephrectomy (Stenzel and deKernion,
1989). The prognosis for patients with metastatic disease is
unfavourable with a 3-year disease-free survival of less than 5%.
Cytotoxic chemotherapy has demonstrated minimal activity for the
treatment of RCC (Yagoda et al, 1995; Motzer et al, 1996). Reports
of spontaneous regression of metastasis and prolonged treatment-
free intervals for metastatic disease support the notion of an
immunologically modulated disease. Immunological therapies
such as interferon 2a (IFNa) and interlukin-2 are more effective
than chemotherapy. Unfortunately, these therapies still only confer
a limited survival advantage with complete response rates between
3 and 9% and partial response between 10 and 18% (reviewed in
Figlin, 2000).
The mechanisms of resistance of RCCs to immunotherapy are
not well defined. The Fas death receptor, which belongs to the
tumour necrosis factor receptor family, is a key physiological
regulator of cell death especially in immunologically mediated
apoptosis (Nagata, 1999). In the kidney, Fas is constitutively
expressed in the cells of the proximal tubules (progenitor cells for
RCC) and also in RCC (Gerharz et al, 1999; Peduto et al, 1999). In
cell culture experiments, the Fas pathway has been shown to be
functional but requiring upregulation for activation of the cell
death pathway (Nonomura et al, 1996; Gerharz et al, 1999; Lee JK
et al, 2000). Cytokines including interferons have been shown to
upregulate Fas in immortalised proximal tubular cells and RCC
lines (Nonomura et al, 1996; Miyake et al, 1998; Sayers et al, 1998;
Wu et al, 2000). Despite induced expression, cultured RCCs can
remain resistant to apoptosis resulting from binding of agonistic
anti-Fas antibodies to Fas receptor (Ramp et al, 2000).
Upon activation through binding to its natural ligand, the
cytoplasmic region of the Fas receptor containing the death
domain recruits and activates pro-caspase-8. Subsequently,
depending on the cell type and/or stimulus, pro-caspase-8 can
directly or indirectly activate caspase-3 to effect apoptosis (Scaffidi
et al, 1998). In an indirect pathway, caspase-8 signalling is
dependant on the mitochondria to transmit the apoptotic signal.
Cytochrome c release from the mitochondria participates with
apoptotic protease activating factor-1 in the activation of caspase-
9, which in turn activates caspase-3 (Scaffidi et al, 1998; Zou et al,
1999). Recent evidence suggests that Fas receptor activation and
apoptosis can be inhibited by Bcl-2 at the stage of cytochrome c
release and caspase-9 activation and by binding and sequestering
caspase-8 (Kawahara et al, 1998; Poulaki et al, 2001).
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sBcl-2 is present in the distal collecting tubular cells of the
normal kidney but upregulated in 20–50% of RCC, which develop
from the proximal tubular cells. Bcl-2 expression has been shown
to be present in a greater proportion of metastatic lesions when
compared to the corresponding primary lesion (Huang et al, 1999;
Lee CT et al, 2000; Zhang and Takenaka, 2000). In RCC cell lines, a
reduction in Bcl-2 has been shown to be associated with increased
sensitivity to anti-Fas (Hara et al, 2001). Based on these
observations, we hypothesised that resistance to IFNa may be
overcome by G3193, an antisense (AS) oligonucleotide targeting
Bcl-2. We demonstrate that IFNa induces Fas and Bcl-2 in two RCC
cell lines. Despite upregulation of Bcl-2, apoptosis evident by
PARP cleavage was induced by anti-Fas in one cell line. In the
resistant cell line, apoptosis could be induced by targeting Bcl-2
with G3139 and then stimulating with IFNa. The results suggest
that G3139 in combination with IFNa may be a therapeutic strategy
for patients with metastatic RCC.
MATERIALS AND METHODS
Cell culture
The human RCC lines, SK-RC-44 and SK-RC-07, were maintained
in MEM/NEAA supplemented with 10% heat-inactivated fetal calf
serum (FCS), 100IUml
 1 penicillin, 100 Mml
 1 streptomycin and
2m ML -glutamine (Life Technologies, Grand Island, NY, USA). In
most experiments, cells were plated in six-well tissue culture plates
at a density of 5 10
5 and were allowed to adhere overnight. For
cell viability studies, cells were plated at a density of 4 10
3 cells
per well in 96-well plates (Becton Dickinson, Franklin, NJ, USA).
Cells were incubated in either medium or in medium containing
the indicated concentrations of recombinant human interferon 2ab
(IFNa) (Schering, Keniworth, NJ, USA) for the specified times.
Fas-induced cell death
Fas-mediated cytotoxicity was induced by addition of the agonistic
crosslinking anti-Fas mAb, CH11 (Immunotech, Marseille, France).
For dose–response experiments, cells were incubated with CH11
at the indicated concentrations; otherwise, CH11 was used at
a concentration of 50ngml
 1. An antagonistic anti-Fas antibody,
ZB4 (Immunotech, Marseille, France), which inhibits apoptosis
induced by CH11, was added where specified at a concentration of
1mgml
 1 1h before the addition of the CH11 antibody. Caspase
activity was determined by the cleavage of poly(ADP–ribose)
polymerase (PARP) detected by Western blotting.
G3139
G3139 (kindly provided by Genta Inc.), an 18-mer phosphothioate
AS targeted at the translation initiation site of the Bcl-2 mRNA,
was used. The G3139, sequence 50-tctcccagcgtgcgccat-30 as well as
reverse sense (RS), sequence 50-taccgcgtgcgaccctct-30 and missense
(MS), sequence 50-tctcccagcatgtgccat-30 controls were obtained
from Genta (Boston, MA, USA). All of the oligonucleotides were
shipped as a lyophilised powder after purification by grade 1
HPLC. When reconstituted, the stock solution was stored at
 201C. Oligonucleotides were combined with a transfection agent
before use. The agent used was a liposome formulation of cationic
lipids Eu.Fectint GC-030/DOPE in a 2:1 ratio (Promega, San Luis
Obispo, CA, USA). A lipid solution was made using serum-free
medium (Opti-MEM, Life Technologies, Grand Island, NY, USA)
so that its concentration equalled 2  the concentration of the
oligonucleotide. The Eu.Fectin-Opti-MEM solution was allowed to
incubate at room temperature for 30–45min so that optimal
formation of liposomes was achieved. It was then combined with
the oligonucleotides for cell transfections.
Western blotting
Cells were washed in phosphate-buffered saline (PBS), scraped
and then lysed at 41C with RIPA buffer containing 1% Nonidet
P40, 1% deoxycholate, 0.1% SDS supplemented with 8mgml
 1
aprotinin, 2mgml
 1 leupeptin and 170mgml
 1 phenylmethylsul-
phonyl fluoride (PMSF) for 30min. After centrifugation, the
protein concentration of the supernatant was determined by
colorimetric analysis using the Bio-Rad protein assay system
(Bio-Rad Laboratories, Richmond, CA, USA). Equal quantities of
lysates (25mg) were separated on either 12% (Bcl-2, Bcl-XL)o r
7.5% (PARP) SDS–PAGE under reducing conditions and trans-
ferred onto enhanced chemiluminescence (ECL) membranes
(Amersham, Arlington Heights, IL, USA). Membranes were then
blocked with 5% milk before incubation with specific antibodies:
M0887 Bcl-2 mouse anti-human (Dako), AM05 Bcl-xl mouse
anti-human (Calbiochem, San Diego, CA, USA), 65196E PARP
mouse anti-human (Pharmingen, San Diego, CA, USA) and
MAB1501 b-actin (Chemicon, Temecula, CA, USA). Bound
antibodies were detected with an anti-mouse/horseradish perox-
idase conjugate (Amersham). An ECL system (Amersham) was
used for detection.
Flow cytometry for Fas
Cells were harvested by scraping, washed once in 2% FCS–MEM
NEAA (staining media) at 41C and then resuspended in staining
media containing 1mgml
 1 bovine serum albumin for 30min.
The cells were pelleted and then resuspended in 2% FCS–PBS
containing ZB4 mouse monoclonal anti-Fas (1:50 dilution)
or isotype control, IgG1 clone 679.1Mc7 (Immunotech, Marseille,
France) for 30min at 41C. The cells were washed once in staining
media and then incubated with FITC-labelled anti-murine IgG
(0810 Immunotech, Marseille, France) in staining media for
30min at 41C. The cells were washed twice in 2% FCS–PBS and
analysed immediately on the flow cytometer. At least 10000 cells
were analysed in each sample and experiments were performed in
triplicate.
MTT assay
RCC cells were plated at a density of 4 10
3 cells per well in
96-well plates (Becton Dickinson, Franklin, NJ, USA). After 24h,
the culture medium was replaced with medium containing IFNa
at the specified concentrations or with culture medium alone.
Viability was determined by use of a colorimetric assay, based on
the reduction of the tetrazolium salt MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide), by mitochondrial dehydro-
genases, in viable cells (Morgan, 1998). After incubations for 48 or
96h, medium was replaced with 200ml MTT reagent (Sigma,
St Louis, MO, USA) (0.5mgml
 1) and allowed to react for 4h at
371C. The solubilising agent dimethyl sulphoxide (DMSO, Fisher
Scientific, Fairlawn, NJ, USA), 100mlwell
 1, was added and the
substrate cleavage was determined at 560nm on a SPECTRAmax
340 microplate reader and analysed using SOFTmax PRO software
(Molecular Devices, Sunnnyvale, CA, USA).
RESULTS
IFNa upregulated Bcl-2 and Fas expression
Bcl-2 protein was constitutively expressed by both SK-RC-44 and
SK-RC-07 cells as detected by Western blotting (Figure 1).
Expression of Bcl-2 increased within 24h of IFNa treatment and
this was sustained at 48h (Figure 1). Fas antigen was constitutively
expressed and incubation with IFNa for 48h increased Fas
expression in SK-RC-44 and SK-RC-07 (Figure 2).
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sEffects of anti-Fas mAb and IFN on cell viability
Fas induction by IFNa prompted examination of the effect of the
anti-Fas antibody (CH11) on cell viability of SK-RC-44 and SK-RC-
07 cells. In a dose–response study conducted over 24h, SK-RC-44
cells exhibited a dose-dependent loss of viability to CH11 over
24h, which could be blocked by preincubation with the anta-
gonistic anti-Fas monoclonal antibody ZB4. In contrast, SK-RC-07
cells did not exhibit a significant response to CH11 (Figure 3A).
As shown in Figure 3B, treatment with IFNa alone for 72h had
little effect on either cell line. However, pretreatment of SK-RC-44
with IFNa for 48h followed by CH11 for 24h markedly enhanced
the anti-Fas-mediated cytotoxicity. This effect was not apparent
in SK-RC-07 in which there was only a modest cytotoxic effect of
CH11 (Figure 3B).
SK-RC-44 cells but not SK-RC-07 can activate Fas-
dependent cleavage of PARP
When induction of Fas by IFNa was followed by Fas ligation with
CH11, there was a significant cytotoxic effect in SK-RC-44 cells
compared to only a modest cytotoxic effect in SK-RC-07. To
determine whether cell death was through apoptosis, PARP
cleavage was examined. PARP-1 is the target of caspase-3, which
cleaves PARP-1 within a DEVD site in the DNA-binding domain,
thus splitting the nuclear localisation sequence into two detectable
fragments. The activation of caspase-3 proteases in response to
Fas/FasL interaction was determined by the cleavage of PARP into
89 and 24kDa fragments (Figure 4) (Lazebnik et al, 1994). IFNa
alone did not cleave PARP in either cell line. When cells were
incubated with only CH11, the appearance of a very weak 89kDa
band indicated that anti-Fas induced PARP cleavage in SK-RC-44
cells after 24h. Pretreatment of SK-RC-44 with IFNa for 48h
followed by CH11 did induce PARP cleavage, which was evident
after 8h and occurred throughout the 24h. In SK-RC-07 cells,
CH11 alone, or following pretreatment of cells with IFNa, did not
induce PARP cleavage.
These data show that failure of the Fas cell death pathway in SK-
RC-07 occurred despite demonstrating that transcription of Fas
mRNA and induction of the Fas antigen. We postulated that the
upregulation of Bcl-2 may inhibit the cytotoxic effect of IFNa and
also prevent cells from responding to the apoptotic stimulus of
CH11.
Downregulation of Bcl-2 with AS G3139
To determine whether downregulation of Bcl-2 sensitised cells to
the IFNa/Fas stimulus, cells were transfected with a Bcl-2 AS
oligonucleotide, G3139. Transmission of the apoptotic signal
following Fas ligation may follow either a direct caspase-8 acti-
vation of caspase-3 pathway or an indirect pathway with a mito-
chondrial intermediate step. Expression of Bcl-2 protein can inhibit
the indirect pathway. Cell transfection rates 480% were achieved
SK-RC-44 SK-RC-07 
NT  24 h  48 h  NT          24 h            48 h 
Bcl-2
-Actin 
Figure 1 Western blot analysis of Bcl-2 protein in cells treated with
IFNa. SK-RC-44 and SK-RC-07 were incubated with 1000Uml
 1 IFNa for
24 and 48h. NT, no treatment control. Protein samples (25mglane
 1)
were probed with an anti-Bcl-2 antibody. In both cell lines, IFNa induced
Bcl-2 expression within 24h and levels were sustained at 48h. Equal
protein loading is shown by reproducing the identical blot with anti-b-actin
antibody.
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Figure 2 Flow cytometry analysis of Fas in cells treated with IFNa. SK-RC-44 and SK-RC-07 cell lines were incubated with IFNa (1000Uml
 1) for the
indicated times. Cell surface staining of Fas was determined in no treatment (NT) controls and 48h after IFNa treatment. Representative overlay histograms;
dotted line IgG1 isotype control antibodies; solid line, Fas antibodies. Fas was constitutively expressed in SK-RC-44 and SK-RC-07 cells. There was a
significant rise in the percentage of Fas-positive SK-RC-44 cells, 34.875.4 vs 68.576.4 (before and after IFNa treatment, respectively) (Po0.003). In SK-RC-
07, Fas increased from 21.874.5 to 36.178.1 following incubation with IFNa (P¼0.03).
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Figure 3 Analysis of anti-Fas antibody and IFNa on the viability of SK-
RC-44 (K) and SK-RC-07 (&) cells by MTT assay. (A) Anti-Fas antibody
CH11 at various concentrations was added to cells that were cultured in
96-well plates (solid line). The antagonistic anti-Fas mAb ZB4 (1mgml
 1)
was added to the culture medium of cells 1h before CH11 (dashed line).
Cell viability was determined after 24h. (B) Cells were cultured with IFNa
at the indicated concentrations for 72h (dashed line), or with IFNa for 72h
and CH11 (50ngml
 1), which was added to each well after 48h (solid
line). Results are expressed as percentage of nontreated control cells (NT).
CH11 was cytotoxic for SK-RC-44, which exhibited a dose response to the
antibody. The loss of cell viability of SK-RC-44 could be blocked by ZB4.
The effect of CH11 on SK-RC-44 cells was markedly enhanced by
pretreatment with IFNa. In comparison, the response of SK-RC-07 cells to
CH11 was limited and not enhanced by pretreatment with IFNa.
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susing a single lipid (GC-030/DOPE). A dose–response study in SK-
RC-07 cells demonstrated effective downregulation of Bcl-2 by
G3139 with little effect of MS or RS controls and less than 10% loss
of cell viability at oligonucleotide concentrations below 300nM and
an Eu.Fectin:oligo ratio of 2:1 (data not shown). Figure 5A
demonstrates the downregulation of Bcl-2 in SK-RC-44 and SK-
RC-07 cells 24h after incubation with G3139. Expression of the
Bclx protein, which shares significant sequence homology with
Bcl-2, was not affected, demonstrating target specificity of the
G3139 oligonucleotide (Figure 5B).
Downregulation of Bcl-2 sensitises IFNa-treated cells to
anti-Fas
In 96-well plates, SK-RC-44 and SK-RC-07 cells were incubated
with G3139, MS, RS or empty lipid controls. After 24h, cells were
treated with IFNa for a further 48h followed by CH11 as previously
described. Single-agent treatment with G3139 reduced the viability
of both SK-RC-44 and SK-RC-07 cells, and the reduction was not
significant when compared to the effect of MS and RS or empty
lipid (Figure 6). Incubation with G3139 followed by IFNa reduced
the viability of SK-RC-44 cells (43.977.9) (Figure 6A). An effect of
  0     8      16       24 h          0         8        16         24 h 
PARP
116 kDa 
85 kDa
SK-RC-44 SK-RC-07
A B
C D
Figure 4 Analysis of PARP cleavage by Western blot. SK-RC-44 and SK-
RC-07 cells were incubated with CH11 (50ngml
 1)( A, B), or pretreated
with IFNa for 48h followed by CH11 (50ngml
 1) for 8, 16 or 24h (C, D).
PARP cleavage was determined at the indicated time points by Western
blot as described in Materials and methods. IFNa did not induce PARP
cleavage in either cell line. CH11 induced a weak PARP cleavage in SK-RC-
44 cells but only after 24h (A). In SK-RC-44 cells pretreated with IFNa,
cleavage of PARP was obvious and occurred within 8h of CH11 being
added to the medium (C). In the SK-RC-07 cells, neither treatment with
CH11 (B) nor with IFNa and CH11 (D) induced PARP cleavage.
Bcl-2 
 -Actin   
SK-RC-44 SK-RC-07 
NT         AS  MS     RS  NT        AS  MS      RS 
SK-RC-44
NT        AS          MS     RS
Bcl-2 
Bclx 
-Actin
A
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Figure 5 Western blot analysis of Bcl-2 following treatment with oligonucleotides. (A) SK-RC-44 and SK-RC-07 cells were plated in six-well plates for
24h (5 10
5cellswell
 1). Cells were incubated with Eu.Fectin/oligonucleotide G3139 AS, MS or RS oligonucleotides at a concentration of 300nM for 4h.
NT, no treatment controls. After 24h, Bcl-2 expression was determined by Western blot. Bcl-2 was downregulated by G3139 AS in SK-RC-44 and SK-RC-
07. At the concentration of 300nM, MS or RS did not cause a significant reduction in Bcl-2 expression in either cell line. (B) Following detection of Bcl-2, a
membrane was stripped and re-probed for Bclx protein. Bcl-2 is downregulated by G3139 AS but Bclx expression is unaffected.
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sMS, RS or empty lipid controls was also seen (cell viability
60.376.9, 61.677.8 and 73.678.5, respectively). The effect of
G3139 and IFNa was significantly greater than controls in SK-RC-
44 cells (Po0.01). G3139 followed by CH11 reduced the viability of
SK-RC-44 cells to 20.773.2, which was significantly greater than
MS, RS or empty lipid (Po0.001). In cells incubated with G3139
and then treated with IFNa and CH11, viability was reduced to
11.273.4 but an effect of MS and RS controls was also evident.
The effect of G3139 on the IFNa/Fas-resistant SK-RC-07 cells is
shown in Figure 6B. G3139 alone did not cause a significant loss of
viability compared to MS or RS controls. G3139 in combination
with IFNa or CH11 did enhance the effect of both agents and was
significantly greater than controls; however, the effect was not
significant (G3139 and IFNa 77.879.6 and G3139 and CH11
74.676.1). There was a synergistic effect when SK-RC-07 cells were
incubated with G3139 and then treated with IFNa followed by
CH11. The combination reduced cell viability to 38.777.2 (MS
75.479.7 and RS 70.6711.2) (Po0.01).
Fas-resistant SK-RC-07 cells cleave PARP upon
downregulation of Bcl-2
To determine if anti-Fas would cleave PARP in Bcl-2 down-
regulated cells, SK-RC-07 cells were incubated with AS or controls
and then IFNa and CH11 (Figure 7). PARP was only cleaved by
CH11 in cells pretreated with G3139 followed by IFNa. G3139/IFNa
and G3139/CH11 had no effect and in addition, PARP cleavage
did not occur in MS or RS controls. Furthermore, cleavage of
PARP by CH11 in G3139/IFNa-treated cells was inhibited by
the addition of ZB4. These results suggest that downregulation of
Bcl-2 permits apoptosis to occur following Fas/FasL interaction in
IFNa-treated cells.
DISCUSSION
Recombinant IFNa has created the first window of opportunity for
the treatment of metastatic RCC. However, complete response
rates to IFNa and/or other immunological agents remain limited.
To date, it is unclear whether IFNa effects are mediated by the
known direct antiproliferative activity in RCC lines or by a direct
cytotoxic effect (Figlin, 1999).
We have shown that RCC lines constitutively express Fas and
that IFNa upregulates Fas as well as the apoptosis-inhibiting Bcl-2
protein. Mechanistically, the observations can be explained by
studies showing that IFNs can activate nuclear factor kB through
an RNA-dependent protein kinase resulting in transcription of bcl-2
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Figure 6 Cell viability following anti-Fas in oligonucleotide- and IFNa-
treated cells. SK-RC-44 (A) and SK-RC-07 (B) cells were cultured in 96-
well plates and incubated with G3139 AS or controls as described in
Materials and methods. After 24h, cells were incubated with IFNa
(1000Uml
 1) for 72h, or with IFNa for 48h followed by CH11
(50ngml
 1) for 24h. Cell viability was assessed by MTT. Results are
expressed as a percentage of untreated controls. Single-agent treatment
with G3139 reduced the viability of both SK-RC-44 and SK-RC-07 cells but
was not significant when compared to the effect of MS and RS. In SK-RC-
44, G3139 followed by CH11 reduced the viability of cells to 20.773.2 and
was significantly greater than the effect of MS or RS (Po0.001). In cells
incubated with G3139 and then treated with IFNa and CH11, viability was
reduced to 11.273.4 but an effect of MS and RS controls was also evident.
The effect of G3139 in combination with IFNa or CH11 did enhance the
effect of both agents in SK-RC-07 cells, but the effect was limited. There
was however a synergistic effect when SK-RC-07 cells were incubated with
G3139 and then treated with IFNa followed by CH11. Cell viability was
reduced to 38.777.2 by this combination and was significantly greater than
in controls.
Oligo −         −    +  +         +      + 
IFN  +         +     +  −         +      +  
CH11 −         +       −  +         +      + 
ZB4 −        −     −  −        −      +
PARP
116 kDa
 85 kDa
1  2                3    4  5           6 
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Figure 7 Analysis of PARP cleavage by Western blot. SK-RC-07 cells
were incubated with G3139 AS (A), MS (B)o rR S( C) oligonucleotides.
Cells were treated with IFNa (1000Uml
 1) for 48h and then by CH11
(50ngml
 1) for 24h as indicated. ZB4 was added to cells 1h before
treatment with CH11 (lane 6). PARP cleavage was determined by Western
blot as described in Materials and methods. SK-RC-07 cells treated with
G3139 were sensitive to the Fas antibody CH11 but only when pretreated
with IFNa (lane 5). Neither treatment with mismatch or RS sensitised cells
to Fas-induced PARP cleavage. PARP cleavage could be inhibited by the
addition of ZB4 before treatment with CH11 (lane 6).
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sgenes as well as Fas (Lee HH et al, 1999; Tan and Katze, 1999;
Harwood et al, 2000).
IFNa did not have a direct cytotoxic effect on either of our cell
lines; however, cleavage of PARP was evident in IFNa-treated
SKRC-44 cells when incubated with anti-Fas antibody CH11. Our
results are in keeping with reports that upregulation of Fas is a
prerequisite for sensitisation of cells to anti-Fas-mediated apop-
tosis (Gerharz et al, 1999; Lee JK et al, 2000). PARP is one substrate
for pro-caspase-8, suggesting that the effect of IFNa was to induce
Fas and that the Fas pathway was subsequently activated and
intact. PARP cleavage was not evident in SKRC-07 cells despite a
significant induction of Fas by IFNa. Fas expression was higher in
SKRC-44 cells, which could explain the differential sensitivity
compared to SKRC-04. That SKRC-07 cells were not responsive
to anti-Fas could be a consequence of the lower level of Fas
expression even after induction by IFNa. We have shown that IFNa
induces Bcl-2 in SKRC-07 cells, which led us to postulate that Bcl-2
rescue of cells could prevent Fas-induced apoptosis. It has been
recently shown that different cell lines can respond differently to
cell death induced by anti-Fas. One class of cells activates caspase-
8 and caspase-3 efficiently and independent of mitochondrial
signals. For this reason, cells are not rescued by Bcl-2 expression.
Other cells do not strongly activate caspase-8 and must use a
signalling pathway that is dependent on mitochondrial death
signals and are thus inhibited by Bcl-2 expression (Scaffidi et al,
1998; Johnson and Boise, 1999). This concept can explain the
reports that IFNa can inhibit apoptosis in some cells (Su and
David, 1999) and, alternatively, induce apoptosis in other cells
(Lee RK et al, 1999). To determine whether inhibition of Bcl-2
expression would sensitise the Fas-resistant cells to anti-Fas, we
used an AS oligonucleotide, G3139. Bcl-2 was effectively down-
regulated by G3139 but not mismatch and RS controls and
target specificity was demonstrated by the preservation of Bclx
expression. Downregulation of Bcl-2 sensitised SKRC-07 cells to
anti-Fas, which was evident following induction of Fas with IFNa.
In these cells, PARP cleavage was inhibited by the antagonistic
antibody ZB4, suggesting that ultimately the cell death stimulus is
initiated through a Fas-dependent pathway. In the Fas-sensitive
SKRC-44 cell line, downregulation of Bcl-2 is an additional but
nonspecific cytotoxic event. AS reduces the cell viability, but this
effect is also seen in RS and MS controls. An explanation for this
effect may be that the transfection of oligo/lipid simply adds insult
to injury in an already dying cell. Interestingly, in the Fas-resistant
SKRC-07 cells, the downregulation of Bcl-2 did not induce a loss of
cell viability to the extent seen in the sensitive line treated with
IFNa and anti-Fas. It is possible that preservation of other
apoptosis-inhibiting Bcl-2 family proteins maintains the survival
signal.
The Fas-mediated apoptosis pathway is present and inducible in
proximal tubular cells of the normal kidney (Jo et al, 2002). This
study has confirmed that IFNa has a cytotoxic effect on RCC lines
by induction of the Fas antigen. The in vitro observation might
explain the complete response rates seen in some patients
following IFNa therapy. G3139 effectively reduced Bcl-2 expression
and enabled Fas-induced apoptosis in a resistant cell line with low
levels of Fas expression. Cell death was Fas dependent and
supports the notion that some cells can activate alternative Fas
pathways, which can be inhibited by Bcl-2. These pathways may be
present to a greater or lesser extent within different cell lines of
RCC. Recently, Bcl-2 has been shown to be upregulated in a
proportion of renal cell metastatic lesions as compared to the
primary lesions (Lee CT et al, 2000). This finding could be a factor
responsible for the resistance of RCC to IFNa therapy. The
demonstration that sensitivity to Fas apoptosis can be enhanced by
downregulation of Bcl-2 suggests that the effectiveness of IFNa can
be improved in vivo.
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